Donepezil

Generic Name: Donepezil

Brand Names: Adlarity, Aricept, Namzaric

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉NO_₃

CAS Number: 120014-06-4

Unique Ingredient Identifier: 8SSC91326P

Background: In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication: Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions: Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Alzheimer's Disease Therapeutics Market With 18.8% CAGR

The Alzheimer’s disease therapeutics market is projected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, at a CAGR of 18.8%, driven by an aging global population and advancements in treatment. North America leads with a 42.5% share in 2023. Key factors include increased awareness, a robust drug pipeline, and rising prevalence of Alzheimer’s disease worldwide.

beingpatient.com

2 months ago

STUDY: Cholinesterase Inhibitors Show Promise for Lewy Body Dementia

A 10-year study by Karolinska Institutet found that cholinesterase inhibitors (ChEIs) like donepezil and galantamine showed promise in reducing cognitive decline in LBD, with rivastigmine reducing mortality risk. Higher ChEI doses provided greater cognitive benefits, but memantine showed no significant cognitive effect. The study highlights the need for long-term follow-ups and the lack of universal benchmarks for cognitive decline reduction.

healio.com

3 months ago

The inside story of Cobenfy

The FDA's approval of Cobenfy (KarXT) marks a significant milestone in psychopharmacology as the first antipsychotic not targeting dopamine 2 receptors. The drug's journey began with xanomeline, synthesized by Novo Nordisk in the 1980s, showing promise in Alzheimer's and schizophrenia studies but shelved by Eli Lilly. Resurrected by Steven M. Paul, MD, who combined it with trospium at Karuna, the drug's approval highlights the industry's potential lapses in foresight and unnecessary delays in bringing effective treatments to market.